SONN (Sonnet BioTherapeutics Holdings) Accounts Payable: $3.75 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SONN Sonnet BioTherapeutics Holdings Inc SONN
28 GF Score
Price $1.26
View Full Analysis

What is Sonnet BioTherapeutics Holdings Accounts Payable?

Sonnet BioTherapeutics Holdings SONN 28 Accounts Payable is $3.75 Mil as of Jun. 2025. GuruFocus rates SONN with a GF Score™ of 28/100.

Sonnet BioTherapeutics Holdings's Accounts Payable for the quarter that ended in Jun. 2025 was $3.75 Mil.

Sonnet BioTherapeutics Holdings's quarterly Accounts Payable increased from Dec. 2024 ($1.64 Mil) to Mar. 2025 ($1.75 Mil) and increased from Mar. 2025 ($1.75 Mil) to Jun. 2025 ($3.75 Mil).

Sonnet BioTherapeutics Holdings's annual Accounts Payable declined from Sep. 2022 ($4.75 Mil) to Sep. 2023 ($2.20 Mil) and declined from Sep. 2023 ($2.20 Mil) to Sep. 2024 ($2.18 Mil).

Sonnet BioTherapeutics Holdings Accounts Payable Related Terms

Sonnet BioTherapeutics Holdings Accounts Payable Historical Data

* Premium members only.

The historical data trend for Sonnet BioTherapeutics Holdings's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sonnet BioTherapeutics Holdings Accounts Payable Chart

Sonnet BioTherapeutics Holdings Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Accounts Payable
Get a 7-Day Free Trial 2.06 3.78 4.75 2.20 2.18

Sonnet BioTherapeutics Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.88 2.18 1.64 1.75 3.75
SONN
28GF Score
Sonnet BioTherapeutics Holdings Inc SONN
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sonnet BioTherapeutics Holdings Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $3.75 Mil mean?
Sonnet BioTherapeutics Holdings (SONN) has a Accounts Payable of $3.75 Mil as of Jun. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Sonnet BioTherapeutics Holdings and its competitors.
Is Sonnet BioTherapeutics Holdings' Accounts Payable too high?
Sonnet BioTherapeutics Holdings' current Accounts Payable is $3.75 Mil. Overall, Sonnet BioTherapeutics Holdings has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Sonnet BioTherapeutics Holdings' Accounts Payable compare to CING and BOLD?
Sonnet BioTherapeutics Holdings' Accounts Payable of $3.75 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Sonnet BioTherapeutics Holdings and its competitors. Sonnet BioTherapeutics Holdings's current Accounts Payable is $3.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonnet BioTherapeutics Holdings stock overvalued right now?
Sonnet BioTherapeutics Holdings (SONN) has a current Accounts Payable of $3.75 Mil. The current Accounts Payable is $3.75 Mil. Sonnet BioTherapeutics Holdings' overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Sonnet BioTherapeutics Holdings (SONN), the current Accounts Payable is $3.75 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sonnet BioTherapeutics Holdings Business Description

Address 100 Overlook Center, Suite 102, Princeton, NJ, USA, 08540
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
28GF Score

Get the complete analysis for SONN

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.26
Price